Screening

Routine screening for BV during pregnancy is not recommended, however there is evidence to support screening and treatment at 12–16 weeks in high-risk pregnancies (i.e., previous preterm labour/delivery or preterm premature rupture of membranes). If the patient is symptomatic or at high risk, test for BV and treat. Treatment of BV in such cases may reduce the risk of prematurity, low birth weight and preterm premature rupture of membranes.

In low-risk and asymptomatic women, screening is not recommended, as it has not been shown to affect adverse outcomes. If symptoms suggest BV, testing is appropriate, and positive results warrant treatment for symptom resolution.